deuremidevir

Deuremidevir is an orally administered nucleoside analogue antiviral drug developed as a broad-spectrum inhibitor of viral replication. It targets the highly conserved RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 and other viruses. After oral administration, deuremidevir is rapidly absorbed and metabolized to its active nucleoside triphosphate form inside cells. This active form covalently binds to the RdRp active center, blocking viral RNA synthesis and thus inhibiting virus replication[1][3][4]. Deuremidevir is a deuterated tri-isobutyrate prodrug of GS-441524 (the main metabolite of remdesivir). It has shown efficacy in phase 3 clinical trials for mild-to-moderate COVID-19 in non-hospitalized adults at risk for disease progression[1][3]. The drug was conditionally approved in China in January 2023 for COVID-19 treatment but later restricted by WHO guidelines to use only within clinical trials due to evolving evidence[3].

Brand names

民得维

Other names

mindeudesivirrenmindevirdeuremidevir hydrobromide